AN2 Therapeutics, Inc.
ANTXAN2 Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule therapeutics using a proprietary boron chemistry platform.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
AN2 Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule therapeutics using a proprietary boron chemistry platform. The company focuses on addressing critical unmet needs in hematologic diseases, infectious diseases, and oncology. Its primary value proposition lies in leveraging the unique binding properties of boron-based molecules to create differentiated treatments for rare and difficult-to-treat conditions.
A clinical-stage innovator utilizing a specialized boron chemistry platform to develop first-in-class or differentiated oral therapies for neglected and rare diseases.
Questions, answered.
- What is AN2 Therapeutics, Inc.'s market cap?
- AN2 Therapeutics, Inc. (ANTX) has a market capitalization of $177.6M and trades on NASDAQ.
- Who are AN2 Therapeutics, Inc.'s competitors?
- AN2 Therapeutics, Inc.'s key competitors include Incyte Corporation, Septerna, Inc. Common Stock, Spruce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does AN2 Therapeutics, Inc. partner with?
- AN2 Therapeutics, Inc.'s notable partners include Anacor Pharmaceuticals, Inc., Brii Biosciences Limited, GSK, and others.
- Where is AN2 Therapeutics, Inc. headquartered?
- AN2 Therapeutics, Inc. is headquartered in United States of America and employs approximately 36 people. It has been publicly traded since 2022.